Article Text

PDF
Original article
Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis
  1. Daryle J DePianto1,
  2. Sanjay Chandriani1,2,
  3. Alexander R Abbas1,
  4. Guiquan Jia1,
  5. Elsa N N'Diaye1,
  6. Patrick Caplazi1,
  7. Steven E Kauder1,
  8. Sabyasachi Biswas1,
  9. Satyajit K Karnik1,3,
  10. Connie Ha1,
  11. Zora Modrusan1,
  12. Michael A Matthay4,
  13. Jasleen Kukreja5,
  14. Harold R Collard4,
  15. Jackson G Egen1,
  16. Paul J Wolters4,
  17. Joseph R Arron1
  1. 1Genentech Research and Early Development, South San Francisco, California, USA
  2. 2Novartis Institutes for Biomedical Research, Emeryville, California, USA
  3. 3Gilead Sciences, Foster City, California, USA
  4. 4Department of Medicine, University of California, San Francisco, California, USA
  5. 5Department of Surgery, University of California, San Francisco, California, USA
  1. Correspondence to Dr Joseph R Arron, Genentech, MS 231C, 1 DNA Way, South San Francisco, CA 94080, USA; arron.joseph{at}gene.com

Abstract

Background There is microscopic spatial and temporal heterogeneity of pathological changes in idiopathic pulmonary fibrosis (IPF) lung tissue, which may relate to heterogeneity in pathophysiological mediators of disease and clinical progression. We assessed relationships between gene expression patterns, pathological features, and systemic biomarkers to identify biomarkers that reflect the aggregate disease burden in patients with IPF.

Methods Gene expression microarrays (N=40 IPF; 8 controls) and immunohistochemical analyses (N=22 IPF; 8 controls) of lung biopsies. Clinical characterisation and blood biomarker levels of MMP3 and CXCL13 in a separate cohort of patients with IPF (N=80).

Results 2940 genes were significantly differentially expressed between IPF and control samples (|fold change| >1.5, p<0.05). Two clusters of co-regulated genes related to bronchiolar epithelium or lymphoid aggregates exhibited substantial heterogeneity within the IPF population. Gene expression in bronchiolar and lymphoid clusters corresponded to the extent of bronchiolisation and lymphoid aggregates determined by immunohistochemistry in adjacent tissue sections. Elevated serum levels of MMP3, encoded in the bronchiolar cluster, and CXCL13, encoded in the lymphoid cluster, corresponded to disease severity and shortened survival time (p<10−7 for MMP3 and p<10−5 for CXCL13; Cox proportional hazards model).

Conclusions Microscopic pathological heterogeneity in IPF lung tissue corresponds to specific gene expression patterns related to bronchiolisation and lymphoid aggregates. MMP3 and CXCL13 are systemic biomarkers that reflect the aggregate burden of these pathological features across total lung tissue. These biomarkers may have clinical utility as prognostic and/or surrogate biomarkers of disease activity in interventional studies in IPF.

  • Idiopathic pulmonary fibrosis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles